Buntanetap tartrate for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 29 Nov 2024: Trial registered, NCT06709014
  2. 4 Feb 2025: Trial started, NCT06709014

The trials

NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

State
Completed
Phase
Phase 2 and Phase 3
People
351 taking part
Started
1 Apr 2023
Primary completion
13 Feb 2024
Arms
7.5mg Buntanetap/Posiphen, 15mg Buntanetap/Posiphen, 30mg Buntanetap/Posiphen
Results
Posted on the registry
  1. 17 Jan 2023: Trial registered
  2. 1 Apr 2023: Trial started
  3. 13 Feb 2024: Trial completed
  4. 29 Apr 2025: Trial results posted

NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

State
Under way
Phase
Phase 3
People
760 planned
Started
4 Feb 2025
Primary completion
Dec 2027
Arms
buntanetap
Results
None posted
  1. 29 Nov 2024: Trial registered
  2. 4 Feb 2025: Trial started

NCT07757204: An Open-label Long-term Safety Study of Buntanetap in Participants With AD

State
Not started
Phase
Phase 2 and Phase 3
People
400 planned
Started
21 Nov 2026
Primary completion
21 Feb 2030
Arms
Single Arm
Results
None posted
  1. 11 Aug 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Buntanetap/Posiphen.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.